keyword
MENU ▼
Read by QxMD icon Read
search

Cancer blood biomarker

keyword
https://www.readbyqxmd.com/read/28212119/the-role-of-biomarkers-in-undiagnosed-men
#1
Hasan Dani, Stacy Loeb
PURPOSE OF REVIEW: This article intends to review biomarkers derived from blood, urine, and tissue that can aid in the diagnosis of prostate cancer (PCa). RECENT FINDINGS: PCa screening requires tools that complement prostate-specific antigen (PSA) with a higher specificity for clinically significant disease. Novel blood biomarkers, such as the Prostate Health Index (phi) and 4Kscore, utilize isoforms of PSA to more accurately predict high-grade PCa than traditional tools such as PSA and the percentage free-to-total PSA...
February 16, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28209906/first-evaluation-of-pet-based-human-biodistribution-and-dosimetry-of-18-f-faza-a-tracer-for-imaging-tumor-hypoxia
#2
Savi Annarita, Elena Incerti, Federico Fallanca, Valentino Bettinardi, Francesca Rossetti, Cristina Monterisi, Antonia Compierchio, Giampiero Negri, Piero Zannini, Luigi Gianolli, Maria Picchio
Fluorine-18 labelled fluoroazomycinarabinoside ((18)F-FAZA) is a positron emission tomography (PET) biomarker for non-invasive identification of regional tumor hypoxia. Aim of the present Phase I study was to firstly evaluate in non-small cell lung cancer patients the human biodistribution and dosimetry of (18)F-FAZA. Methods: Five patients awaiting surgical resection after histologically proven or radiologically suspected non-small cell lung cancer were prospectively enrolled for the study. The patients underwent a PET/computed tomography (CT) study after the injection of 371±32 MBq of (18)F-FAZA...
February 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28209595/prediagnosis-leukocyte-telomere-length-and-risk-of-ovarian-cancer
#3
Meng Yang, Jennifer Prescott, Elizabeth M Poole, Megan S Rice, Laura D Kubzansky, Annika Idahl, Eva Lundin, Immaculata De Vivo, Shelley S Tworoger
Background: The associations between telomere length and cancer risk are equivocal, and none have examined the association between prediagnosis leukocyte telomere length (LTL) and the risk of developing ovarian cancer.Methods: We prospectively measured LTL collected from 442 ovarian cancer cases and 727 controls in the Nurses' Health Studies and the Northern Sweden Health and Disease Study. Cases were matched to one or two controls on age, menopausal status, and date of blood collection. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression...
February 16, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28208771/detecting-blood-based-biomarkers-in-metastatic-breast-cancer-a-systematic-review-of-their-current-status-and-clinical-utility
#4
REVIEW
A M Sofie Berghuis, Hendrik Koffijberg, Jai Prakash, Leon W M M Terstappen, Maarten J IJzerman
Reviews on circulating biomarkers in breast cancer usually focus on one single biomarker or a selective group of biomarkers. An overview summarizing the discovery and evaluation of all blood-based biomarkers in metastatic breast cancer is lacking. This systematic review aims to identify the available evidence of known blood-based biomarkers in metastatic breast cancer, regarding their clinical utility and state-of-the-art position in the validation process. The initial search yielded 1078 original studies, of which 420 were assessed for eligibility...
February 9, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28197929/epithelial-mesenchymal-transition-emt-and-non-small-cell-lung-cancer-nsclc-a-mutual-association-with-airway-disease
#5
Malik Quasir Mahmood, Chris Ward, Hans Konrad Muller, Sukhwinder Singh Sohal, Eugene Haydn Walters
NSCLC is a leading cause of morbidity and mortality worldwide. It includes adeno- and squamous cell carcinoma. In the background, COPD and smoking play a vital role in development of NSCLC. Local progression and metastasis of NSCLC has been associated with various mechanisms, but in particular by a process called epithelial mesenchymal transition (EMT), which is implicated in COPD pathogenesis. In this study, we have investigated whether expression of EGFR (activation marker) and S100A4, vimentin and N-cadherin (as EMT) is different both in central and leading edge of NSCLC and to what extent related to EMT activity of both small and large airways, stage and differentiation of NSCLC...
March 2017: Medical Oncology
https://www.readbyqxmd.com/read/28197362/prognostic-impact-of-the-expression-of-ncr1-and-ncr3-nk-cell-receptors-and-pd-l1-on-advanced-non-small-cell-lung-cancer
#6
Laetitia Fend, Sylvie Rusakiewicz, Julien Adam, Bérangère Bastien, Anne Caignard, Meriem Messaoudene, Christina Iribarren, Isabelle Cremer, Aurélien Marabelle, Christophe Borg, Michaela Semeraro, Luc Barraud, Jean-Marc Limacher, Alexander Eggermont, Guido Kroemer, Laurence Zitvogel
The putative contribution of natural killer (NK) cells to immunosurveillance in non-small cell lung cancer (NSCLC) has been an ongoing conundrum. Here, we used a readily standardizable quantitative real time polymerase chain reaction (qRT-PCR) to measure the expression of NK cell receptors in total peripheral blood mononuclear cells (PBMC) from healthy volunteers (HV), patients with gastrointestinal stromal tumors (GIST), neuroblastoma (NB), melanoma or NSCLC. We quantified NCR1 (which codes for NKp46) and NCR3 (which codes for NKp30), as well as that of three NCR3 splice variants (which give rise to immunostimulatory NKp30A and NKp30B, as well as to immunosuppressive NKp30C)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28196386/-liquid-biopsy-detection-of-molecular-markers-for-treatment-decisions-in-lung-cancer
#7
W M Brückl, R M Wirtz, T Bertsch, J H Ficker, A Jung
Personalized, individualized, targeted therapy has successfully found entrance in the palliative treatment of lung cancer as they enable a personalized and individualized strategy going ahead with biomarker testing. Due to the crescending amount of predictive molecular and immunhistochemical analyses at different time points during therapy the need for more and actual tumor tissue increases; however these samples cannot always be obtained without major discomfort for the patients. Therefore, analyses from blood, the so called "liquid biopsy", is an alternative or additional method...
February 14, 2017: Pneumologie
https://www.readbyqxmd.com/read/28194439/an-early-biomarker-algorithm-predicts-lethal-graft-versus-host-disease-and-survival
#8
Matthew J Hartwell, Umut Özbek, Ernst Holler, Anne S Renteria, Hannah Major-Monfried, Pavan Reddy, Mina Aziz, William J Hogan, Francis Ayuk, Yvonne A Efebera, Elizabeth O Hexner, Udomsak Bunworasate, Muna Qayed, Rainer Ordemann, Matthias Wölfl, Stephan Mielke, Attaphol Pawarode, Yi-Bin Chen, Steven Devine, Andrew C Harris, Madan Jagasia, Carrie L Kitko, Mark R Litzow, Nicolaus Kröger, Franco Locatelli, George Morales, Ryotaro Nakamura, Ran Reshef, Wolf Rösler, Daniela Weber, Kitsada Wudhikarn, Gregory A Yanik, John E Levine, James L M Ferrara
BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) prior to the onset of GVHD symptoms. METHODS. Patient blood samples on day 7 after HCT were obtained from a multicenter set of 1,287 patients, and 620 samples were assigned to a training set. We measured the concentrations of 4 GVHD biomarkers (ST2, REG3α, TNFR1, and IL-2Rα) and used them to model 6-month NRM using rigorous cross-validation strategies to identify the best algorithm that defined 2 distinct risk groups...
February 9, 2017: JCI Insight
https://www.readbyqxmd.com/read/28194229/circulating-and-tissue-biomarkers-in-early-stage-non-small-cell-lung-cancer
#9
Caterina Fumagalli, Fabrizio Bianchi, Paola Rafaniello Raviele, Davide Vacirca, Giovanni Bertalot, Cristiano Rampinelli, Matteo Lazzeroni, Bernardo Bonanni, Giulia Veronesi, Nicola Fusco, Massimo Barberis, Elena Guerini-Rocco
OBJECTIVE: We sought to characterise circulating and tissue tumour biomarkers of patients who developed early-stage non-small cell lung cancer (NSCLC) during long-term follow-up of a chemoprevention trial (NCT00321893). MATERIALS AND METHODS: Blood and sputum samples were collected from 202 high-risk asymptomatic individuals with CT-detected stable lung nodules. Real-time PCR was performed on plasma to quantify free circulating DNA. Baseline serum was investigated with a previously validated test based on 13 circulating miRNAs (miR-Test)...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28193016/a-cysteine-specific-fluorescent-switch-for-monitoring-oxidative-stress-and-quantification-of-aminoacylase-1-in-blood-serum
#10
Anila H A, Firoj Ali, Shilpi Kushwaha, Nandaraj Taye, Samit Chattopadhyay, Amitava Das
Reagents that allows detection and monitoring of crucial biomarkers with luminescence ON response have significance in clinical diagnostics. A new coumarin derivative is reported here, which could be used for specific and efficient chemodosimetric detection of cysteine, an important biomarker. The probe is successfully used for studying the biochemical transformation of N-acetylcysteine, a commonly prescribed Cys supplement drug to Cys by aminoacylase-1 (ACY-1), an important and endogenous mammalian enzyme...
December 20, 2016: Analytical Chemistry
https://www.readbyqxmd.com/read/28192399/c-met-mir-130b-axis-as-novel-mechanism-and-biomarker-for-castration-resistance-state-acquisition
#11
A Cannistraci, G Federici, A Addario, A L Di Pace, L Grassi, G Muto, D Collura, M Signore, L De Salvo, S Sentinelli, G Simone, M Costantini, S Nanni, A Farsetti, V Coppola, R De Maria, D Bonci
Although a significant subset of prostate tumors remain indolent during the entire life, the advanced forms are still one of the leading cause of cancer-related death. There are not reliable markers distinguishing indolent from aggressive forms. Here we highlighted a new molecular circuitry involving microRNA and coding genes promoting cancer progression and castration resistance. Our preclinical and clinical data demonstrated that c-Met activation increases miR-130b levels, inhibits androgen receptor expression, promotes cancer spreading and resistance to hormone ablation therapy...
February 13, 2017: Oncogene
https://www.readbyqxmd.com/read/28191452/circulating-tumor-cells-in-genitourinary-malignancies-an-evolving-path-to-precision-medicine
#12
REVIEW
Cory M Hugen, Daniel E Zainfeld, Amir Goldkorn
Precision medicine with molecularly directed therapeutics is rapidly expanding in all subspecialties of oncology. Molecular analysis and treatment monitoring require tumor tissue, but resections or biopsies are not always feasible due to tumor location, patient safety, and cost. Circulating tumor cells (CTCs) offer a safe, low-cost, and repeatable tissue source as an alternative to invasive biopsies. "Liquid biopsies" can be collected from a peripheral blood draw and analyzed to isolate, enumerate, and molecularly characterize CTCs...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28187292/snapshot-circulating-tumor-cells
#13
Caroline Dive, Ged Brady
Circulating tumor cells in the blood of patients are both signal flares for the existence of a tumor and harbingers of metastasis. With recent technological developments, these cells can be isolated and analyzed to provide insights into the biology of cancer spread and response to therapy and to offer new avenues for blood biomarker development.
February 9, 2017: Cell
https://www.readbyqxmd.com/read/28186965/cell-free-dna-detected-by-liquid-biopsy-as-a-potential-prognostic-biomarker-in-early-breast-cancer
#14
Roberta Maltoni, Valentina Casadio, Sara Ravaioli, Flavia Foca, Maria Maddalena Tumedei, Samanta Salvi, Filippo Martignano, Daniele Calistri, Andrea Rocca, Alessio Schirone, Dino Amadori, Sara Bravaccini
As conventional biomarkers for defining breast cancer (BC) subtypes are not always capable of predicting prognosis, search for new biomarkers which can be easily detected by liquid biopsy is ongoing. It has long been known that cell-free DNA (CF-DNA) could be a promising diagnostic and prognostic marker in different tumor types, although its prognostic value in BC is yet to be confirmed. This retrospective study evaluated the prognostic role of CF-DNA quantity and integrity of HER2, MYC, BCAS1 and PI3KCA, which are frequently altered in BC...
February 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28186469/blood-based-nucleic-acid-biomarkers-as-a-potential-tool-to-determine-radiation-therapy-response-in-non-small-cell-lung-cancer
#15
Christopher R Deig, Marc S Mendonca, Tim Lautenschlaeger
Lung cancer is the leading cause of cancer deaths worldwide, with smoking as the main risk factor. The use of low-dose computed tomography (LDCT) as a screening method has shown a 20% lung cancer specific mortality benefit; however, widespread implementation is estimated to add $1.3-$2.0 billion in annual national health care expenditures. Blood-based microRNAs (miRNAs), have been investigated in detail and found to be potentially useful biomarkers indicating the presence of lung cancer, especially when used as a companion test to LDCT...
February 10, 2017: Radiation Research
https://www.readbyqxmd.com/read/28186326/automated-image-analysis-of-intra-tumoral-and-peripheral-endocrine-organ-vascular-bed-regression-using-fibrelength-as-a-novel-structural-biomarker
#16
Adam Hargreaves, Alison Bigley, Shirley Price, Jane Kendrew, Simon T Barry
The study of vascular modulation has received a great deal of attention in recent years as knowledge has increased around the role of angiogenesis within disease contexts such as cancer. Despite rapidly expanding insights into the molecular processes involved and the concomitant generation of a number of anticancer vascular modulating chemotherapeutics, techniques used in the measurement of structural vascular change have advanced more modestly, particularly with regard to the preclinical quantification of off-target vascular regression within systemic, notably endocrine, blood vessels...
February 10, 2017: Journal of Applied Toxicology: JAT
https://www.readbyqxmd.com/read/28185687/circulating-tumor-cells-and-circulating-tumor-dna-what-surgical-oncologists-need-to-know
#17
REVIEW
L Cabel, C Proudhon, P Mariani, D Tzanis, G Beinse, I Bieche, J-Y Pierga, F-C Bidard
As a result of recent progress in detection techniques, circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) can now be accurately detected in the blood of most cancer patients. While these new biomarkers can provide a better understanding of key biological mechanisms underlying cancer growth and dissemination, they also open up a wide range of possible clinical applications in medical oncology, radiation oncology and surgical oncology. In this review, we summarize the results obtained with ctDNA and CTC together with their potential future clinical applications in the field of surgical oncology, with particular focus on the perioperative setting of various types of cancer...
January 29, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28184256/immunomethylomic-approach-to-explore-the-blood-neutrophil-lymphocyte-ratio-nlr-in-glioma-survival
#18
John K Wiencke, Devin C Koestler, Lucas A Salas, Joseph L Wiemels, Ritu P Roy, Helen M Hansen, Terri Rice, Lucie S McCoy, Paige M Bracci, Annette M Molinaro, Karl T Kelsey, Margaret R Wrensch, Brock C Christensen
BACKGROUND: Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term "immunomethylomics" to describe the application of these immune lineage DMRs to studying leukocyte profiles. Here, we applied this approach to peripheral blood DNA from 72 glioma patients with molecularly defined brain tumors, representing common patient groups with defined characteristic survival times and risk factors...
2017: Clinical Epigenetics
https://www.readbyqxmd.com/read/28183993/multiparametric-imaging-of-tumor-hypoxia-and-perfusion-with-18-f-fmiso-dynamic-pet-in-head-and-neck-cancer
#19
Milan Grkovski, Heiko Schöder, Nancy Lee, Sean D Carlin, Bradley Jay Beattie, Nadeem Riaz, Jonathan E Leeman, Joseph A O'Donoghue, John Laurence Humm
Tumor hypoxia and perfusion are independent prognostic indicators of patient outcome. We developed the methodology for, and investigated the utility of multiparametric imaging of tumor hypoxia and perfusion with (18)F-fluoromisonidazole (FMISO) dynamic positron emission tomography (dPET) in head and neck cancer (HNC). Methods: 120 HNC patients underwent 0-30 min FMISO dPET in a customized immobilization mask, followed by 10 min static acquisitions starting at 93±6 and 160±13 min post-injection. A total of 248 lesions (≥2 cm(3)) were analyzed...
February 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28183321/biomarker-analysis-of-the-neosphere-study-pertuzumab-trastuzumab-and-docetaxel-versus-trastuzumab-plus-docetaxel-pertuzumab-plus-trastuzumab-or-pertuzumab-plus-docetaxel-for-the-neoadjuvant-treatment-of-her2-positive-breast-cancer
#20
Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, Young-Hyuck Im, Tadeusz Pienkowski, Mei-Ching Liu, Ling-Ming Tseng, Mitch Dowsett, Lila Zabaglo, Sarah Kirk, Tania Szado, Jennifer Eng-Wong, Lukas C Amler, Pinuccia Valagussa, Luca Gianni
BACKGROUND: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations between human epidermal growth factor receptor 2 (HER2) pathway-related biomarkers and clinical outcome in response to these regimens. METHODS: Tumor, serum, and whole blood samples were collected at baseline and post neoadjuvant treatment before surgery...
February 9, 2017: Breast Cancer Research: BCR
keyword
keyword
31097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"